Supressing mortalin-p53 interaction by siRNA pharmacological tools such as MKT-077, Withaferin A, and mortalin protein suppressors leads to growth arrest and apoptosis, supporting the dominant p53 inhibitory role of mortalin in malignant tumors (Wadhwa et al., 2000; Wadhwa et al., 2002; Wadhwa et al., 2003a; Kaul et al., 2005; Yoo et al., 2010; Sane et al., 2014; Nigam et al., 2015). Here, TP53 is linked to cancer.